Moderna, Inc.
NASDAQ:MRNABiotechnology
+$2.48 today
- Market cap
- $79.63B
- Beta
- 1.03
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$8.09
Volume 6.91M
Average 6.53M
MRNA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Moderna, Inc.NASDAQ: MRNA
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $282M rose 5.2% year over year, ahead of the -7.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 30.6% from the prior quarter. Over 3 fiscal years it compounded at -3.5% a year.
Context
- Selling, general & admin amounted to 52.4% of revenue in FY2025, up 15.7 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 14 analysts of $553.79M (-45.6%) for the fiscal year ending Dec 2026, a slowdown from the -13.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $282M+30.6% QoQ
- Last fiscal yearDec 2025
- $1.02B-13.3% YoY
- LTMSep 2026
- $979M-7.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 1.02B USD
- Year-over-year change
- -13.3%
- 4-year CAGR
- +15.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.02B | -13.3% |
| FY2024 | 2024-12-31 | 1.17B | -24.2% |
| FY2023 | 2023-12-31 | 1.55B | +36.8% |
| FY2022 | 2022-12-31 | 1.13B | +99.6% |
| FY2021 | 2021-12-31 | 567M | — |
Selling, General & Admin vs competitors
How MRNA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.7% is the 5th highest of 9, against a peer median of -6.7%.
- Selling, general & admin amounts to 38.8% of revenue for MRNA, versus a peer median of 29.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.46B USD | +48531.9% | -28.7% | — | |
| LTM Jun 2026 | $13.72B USD | -1.7% | +0.3% | 21.5% | |
| LTM Jun 2026 | £9.2B GBP | -13.8% | +2.8% | 27.7% | |
| LTM Sep 2026 | $979M USD | -7.7% | -3.5% | 38.8% | |
| LTM Jun 2026 | €788.8M EUR | +45.9% | +8.9% | 29.8% | |
| LTM Jun 2026 | $132.67M USD | +14.1% | +48.1% | — | |
| LTM Mar 2026 | $127.98M USD | -57.1% | -32.5% | 21.5% | |
| LTM Mar 2026 | €70.46M EUR | -23.0% | +9.1% | 45.1% | |
| LTM Mar 2026 | $69.19M USD | — | — | 105.6% | |
| LTM Mar 2026 | $43.57M USD | -11.6% | +0.0% | 96.1% | |
| Peer median (excluding MRNA) | — | -6.7% | +1.5% | 29.8% | |
Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.74B | 18.88B | 6.85B | 3.2B | 1.94B |
| Cost of Revenue | 2.62B | 5.42B | 4.69B | 1.46B | 868M |
| Gross Profit | 15.12B | 13.46B | 2.16B | 1.74B | 1.08B |
| Gross Margin | 85.2% | 71.3% | 31.5% | 54.2% | 55.3% |
| Research & Development | 1.99B | 3.3B | 4.85B | 4.54B | 3.13B |
| Selling, General & Admin | 567M | 1.13B | 1.55B | 1.17B | 1.02B |
| Operating Expenses | 1.82B | 4.04B | 6.39B | 5.68B | 4.15B |
| Depreciation & Amortization | 232M | 348M | 621M | 189M | 215M |
| EBITDA | 13.54B | 9.95B | (3.28B) | (3.39B) | (2.55B) |
| EBITDA Margin | 76.3% | 52.7% | -47.9% | -106.1% | -131.3% |
| Operating Income | 13.3B | 9.42B | (4.24B) | (3.95B) | (3.07B) |
| Operating Margin | 75.0% | 49.9% | -61.9% | -123.3% | -158.1% |
| Interest Income | 18M | 200M | 421M | 425M | 314M |
| Interest Expense | 18M | 29M | 38M | 24M | 10M |
| Other Income / Expenses | (11M) | 155M | 297M | 338M | 306M |
| Income Before Tax | 13.29B | 9.58B | (3.94B) | (3.61B) | (2.77B) |
| Pre-Tax Margin | 74.9% | 50.7% | -57.6% | -112.8% | -142.4% |
| Income Tax Expense | 1.08B | 1.21B | 772M | (46M) | 54M |
| Net Income | 12.2B | 8.36B | (4.71B) | (3.56B) | (2.82B) |
| Net Margin | 68.8% | 44.3% | -68.8% | -111.3% | -145.2% |
| EPS (Basic) | 30.31 | 21.26 | (12.34) | (9.27) | (7.26) |
| EPS (Diluted) | 28.29 | 20.10 | (12.34) | (9.27) | (7.26) |
| Weighted Avg Shares | 403M | 394M | 382M | 384M | 389M |
| Weighted Avg Shares (Diluted) | 431M | 416M | 382M | 384M | 389M |
Moderna, Inc.
NASDAQ:MRNA
Intrinsic Alpha fair value
Locked
Current Price
$196.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.